A Study ROP116991, Clinical Evaluation of 18 to 24mg/Day Ropinirole CR for Parkinson's Disease
Phase of Trial: Phase III
Latest Information Update: 20 Nov 2017
At a glance
- Drugs Ropinirole (Primary)
- Indications Parkinson's disease
- Focus Registrational; Therapeutic Use
- Sponsors GlaxoSmithKline
- 17 Oct 2017 Status changed from completed to discontinued.
- 27 Jul 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 07 Jul 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.